Hydromorphone controlled release

Drug Profile

Hydromorphone controlled release

Alternative Names: AP 77; Dilaudid; Dilaudid Oros; Exalgo; Hydromorphone extended release; Hydromorphone HCl; Hydromorphone hydrochloride; Jurnista; NMED-1077; OROS® Hydromorphone

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Therapeutic Discovery Corporation
  • Developer ALZA Corporation; Fresenius Kabi; Johnson & Johnson; Mallinckrodt Inc.
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cancer pain; Pain

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 16 Feb 2017 Launched for Pain in USA (Parenteral) before February 2017
  • 11 Jun 2015 No recent reports of development identified - Phase-III for Cancer pain in Taiwan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top